Pliant Therapeutics, Inc. (PLRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.01 |
| Open | 7.99 |
| Bid | 7.60 x 1400 |
| Ask | 7.80 x 1800 |
| Day's Range | 7.44 - 8.08 |
| 52 Week Range | 3.96 - 28.80 |
| Volume | |
| Avg. Volume | 297,301 |
| Market Cap | 276.419M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.57 |
| Earnings Date | Mar 14, 2022 - Mar 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.67 |
- GlobeNewswire
Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial
SOUTH SAN FRANCISCO, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the presentation of two scientific posters at the International Liver Congress™ (ILC) 2022 of the European Association for the Study of the Liver (EASL), taking place June 22-26, 2022, in London, United Kingdom. “Our presentations at this year’s Intern
- GlobeNewswire
Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies
- IND submission of a novel α7β1 integrin activating allosteric antibody anticipated by year end 2022 SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) presented new preclinical data highlighting the potential of PLN-101325, an α7β1 integrin activating antibody​ for the treatment of muscular dystrophies, including Duchenne Muscular Dystrophy (DMD). These data were presented at the New Directions in Biology and Disease of Skeletal Muscle Confe
- GlobeNewswire
Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration
Integrin target selected for development under 2019 collaboration following successful validation by PliantPliant to receive $4 million milestone payment and reimbursement in support of initiation of research and development activities SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the advancement
